ArticleBMC cancer2020
Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Impact of combined vascular resection on short and long-term results following radical surgery for hilar cholangiocarcinoma: evidence from a systematic assessment.World journal of surgical oncology · 2026Pooled it
- [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer].Chirurgie (Heidelberg, Germany) · 2022Pooled it
- The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review.Frontiers in oncology · 2022Pooled it
- Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2022Trial
- Surgical Safety after Preoperative Chemotherapy for Perihilar Cholangiocarcinoma: Multi-Institutional Propensity-Matched Analysis.Annals of surgical oncology · 2026Observational
- Anatomic-Biologic Borderline Resectability Criteria Improve Recurrence Risk Stratification in Perihilar Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Perioperative approaches for patients with biliary tract cancer.Nature reviews. Clinical oncology · 2026Review
- Changing concepts in perihilar cholangiocarcinoma resections and surgery.International journal of surgery (London, England) · 2026Article
- Applying liver transplant techniques in complex liver resection for patients with hilar cholangiocarcinoma: in situ hypothermic portal perfusion without VV bypass.World journal of surgical oncology · 2025Article
- Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes.Journal of gastrointestinal cancer · 2024Article
- Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report.World journal of gastrointestinal oncology · 2024Article
- A contemporary view on vascular resections and reconstruction during hepatectomies.Updates in surgery · 2024Review
- Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.Cancers · 2024Review
- Inside stent placement is suitable for preoperative biliary drainage in patients with perihilar cholangiocarcinoma.BMC gastroenterology · 2024Article
- The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review.Cancers · 2024Review
- Development and validation of a novel preoperative clinical model for predicting lymph node metastasis in perihilar cholangiocarcinoma.BMC cancer · 2024Article
- Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma.Cancers · 2024Review
- The State of Systematic Therapies in Clinic for Hepatobiliary Cancers.Journal of hepatocellular carcinoma · 2024Review
- Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Systemic Treatment for Cholangiocarcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with perihilar cholangiocarcinoma have been unsatisfactory. We established new anatomical resectability classification for patients with localized perihilar cholangiocarcinoma and performed neoadjuvant chemotherapy followed by curative-intent surgery based on its resectability classification and lymph node status to improve prognosis. This study aimed to clarify the long-term outcomes and validation of our strategy.
methodsBetween September 2010 and August 2018, 72 consecutive patients with perihilar cholangiocarcinoma were classified into three groups: Resectable (R = 29), Borderline resectable (BR = 23), and Locally advanced (LA = 20), based on the two factors of tumor vascular and biliary extension. R with clinically lymph node metastasis, BR, and LA patients received neoadjuvant chemotherapy using gemcitabine plus S-1.
resultsForty-seven patients (65.3%) received neoadjuvant chemotherapy: R in 8, BR in 21, and 18 in LA, respectively. Fifty-nine patients (68.1%) underwent curative-intent surgery: R in 26, BR in 17, and LA in 6. Five-year disease-specific survival was 31.5% (median survival time: 33.0 months): 50.3% (not reached) in R, 30.0% (31.4 months) in BR, and 16.5% (22.5 months) in LA, which were relatively stratified. Among 49 patients with resection, disease-specific survival was 43.8% (57.0 months): 57.6% (not reached) in R, 41.0% (52.4 months) in BR, and 0% (49.4 months) in LA, which were significantly good prognosis compared to 23 patients without resection (17.2 months). Multivariate analysis identified preoperative high carcinoembryonic antigen levels (more than 8.5 ng/ml) and pT4 as independent poor prognostic factor of patients with resection.
conclusionNeoadjuvant chemotherapy based on resectability classification and lymph node status was feasible, and was considered efficacious in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.